ImmunoPrecise Antibodies Ltd News - IPA

ImmunoPrecise Increases Financing to $2.3 Million and Makes Payment in Respect of Deferred Purchase Price for IPA Europe and ...

ImmunoPrecise Increases Financing to $2.3 Million and Makes Payment in Respect of Deferred Purchase Price for...

ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX

ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition...

ImmunoPrecise Updates on State and Federal Funding

ImmunoPrecise Updates on State and Federal Funding Canada NewsWire FARGO, ND, April 24, 2020 IPA Awarded Grant...

ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2...

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a...

ImmunoPrecise Announces Agreement with Janssen

ImmunoPrecise Announces Agreement with Janssen Canada NewsWire VICTORIA and CAMBRIDGE, MA, April 14, 2020...

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer Canada...

ImmunoPrecise Announces Extension of Debentures and Completion of Debt Settlement of Previously Issued Debentures

ImmunoPrecise Announces Extension of Debentures and Completion of Debt Settlement of Previously Issued...

L'OCRCVM permet la reprise de la négociation - IPA

L'OCRCVM permet la reprise de la négociation - IPA Canada NewsWire VANCOUVER, le 30 mars 2020 VANCOUVER, le 30 mars 2020 /CNW/ - Reprise...

IIROC Trading Resumption - IPA

IIROC Trading Resumption - IPA Canada NewsWire VANCOUVER, March 30, 2020 VANCOUVER, March 30, 2020 /CNW/ - Trading resumes in: Company:...

ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus fo...

ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA)

Professional-Grade Tools, for Individual Investors.

IPA News

ImmunoPrecise Increases Financing to $2.3 Million and Makes Payment in Respect of Deferred Purchase Price for IPA Europe and ...

ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX

ImmunoPrecise Updates on State and Federal Funding

ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine

ImmunoPrecise Announces Agreement with Janssen

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer

ImmunoPrecise Announces Extension of Debentures and Completion of Debt Settlement of Previously Issued Debentures

L'OCRCVM permet la reprise de la négociation - IPA

IIROC Trading Resumption - IPA

ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus fo...

Suspension de la négociation par l'OCRCVM - IPA

IIROC Trading Halt - IPA

ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic

ImmunoPrecise Reports Record Quarterly and Nine Month Revenue and Positive Adjusted EBITDA

IPA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA) News

ImmunoPrecise Antibodies Ltd (IPA)

Professional-Grade Tools, for Individual Investors.

IPA News

ImmunoPrecise Increases Financing to $2.3 Million and Makes Payment in Respect of Deferred Purchase Price for IPA Europe and ...

ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX

ImmunoPrecise Updates on State and Federal Funding

ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine

ImmunoPrecise Announces Agreement with Janssen

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer

ImmunoPrecise Announces Extension of Debentures and Completion of Debt Settlement of Previously Issued Debentures

L'OCRCVM permet la reprise de la négociation - IPA

IIROC Trading Resumption - IPA

ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus fo...

Suspension de la négociation par l'OCRCVM - IPA

IIROC Trading Halt - IPA

ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic

ImmunoPrecise Reports Record Quarterly and Nine Month Revenue and Positive Adjusted EBITDA

IPA Discussion

Your Recent History